Management of Device Detected AT and Impact of Device Treatment Algorithms on Atrial Fibrillation
| 대상 질환 | Cardiovascular Diseases |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | Medtronic Cardiac Rhythm and Heart Failure |
| 상태 | 조기 종료 |
| 참여자 수 | 79 명 |
| 중재(약물) | Treatment arm |
| 시작일 | 2019년 10월 1일 |
| 완료일 | 2021년 7월 15일 |
| 결과 공개일 | 2026년 2월 27일 |
요약
The MANDATE-AF study was designed to address evidence needs in India for device-based management of AF using AT/AF (Atrial Tachycardia/Atrial fibrillation) diagnostic features and therapies such as Reactive Atrial anti tachycardia Pacing (rATP) within Medtronic Cardiac Implantable Electronic Devices (CIED)and its impact on the time to persistent AF and progression of AT/AF.
Incidence of 'Persistent AF' Over Time
| Control Arm | 0 percentage probability |
|---|---|
| Treatment Arm | 0 percentage probability |
| Control Arm | 0 percentage probability |
| Treatment Arm | 0 percentage probability |
| Control Arm | 0 percentage probability |
| Treatment Arm | 6.7 percentage probability |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
- Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
- Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
- Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
- Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation — Massachusetts General Hospital
- Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With N — Intermountain Health Care, Inc.